

Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)

Technology appraisal guidance

Published: 3 May 2023

www.nice.org.uk/guidance/ta884

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals has confirmed that it does not intend to make an evidence submission for the appraisal at this time. Novartis Pharmaceuticals considers that the technology is unlikely to be used at this point in the treatment pathway.

Information

If NHS organisations wish to consider capmatinib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-5170-3

Accreditation

